Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
GeneThera and Leading Italian Research Institute Finalize Collaboration Agreement on Mad-Cow & Other Animal Diseases
GeneThera, Inc. recently announced the finalization, subject to final translation, of a Collaboration Agreement with Italy’s leading applied research laboratory, Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER) to collaborate on scientific research related to the diagnosis of animal transmittable diseases, such as Mad-Cow and Scrapie diseases.
The Parties to this Agreement will endeavor to validate GeneThera’s proprietary technology by comparing 10,000 samples between GeneThera’s developed test and an approved Post Mortem test under ESFA guidelines for validation. Basically, GeneThera will be responsible for supervising all aspects of the testing under this Agreement, while the Institute will provide its facilities and assist in the accreditation and validation of the tests and technology of GeneThera.
The Agreement will allow for the:
(i) establishment of validation protocols to compare GeneThera’s live animal blood test technology for the detection of Transmissible Spongiform Encephalopathy (”TSE”) to current available methodologies for “post mortem detection” of TSE;
(ii) to establish a research protocol for a time course correlation study between the TSE-specific gene marker expression levels in blood and the presence of TSE in live experimentally infected animals, and
(iii) to establish a Bovine Spongiform Encephalopathy (”BSE”) screening program using GeneThera’s live animal blood test system for large scale cattle testing in feedlots and slaughter houses.
In conjunction with this announcement, IZSLER has begun collecting the first samples from the Institutes’s experimentally infected cattle herd with GeneThera’s Field Collection System(TM) for review by GeneThera’s staff.
Dr. Tony Milici, CEO of GeneThera remarked, “This is a banner day for our Company. The long-awaited day for us to begin large scale validation of our live test for detection of TSE is at hand. We have waited many years for this opportunity and are extremely excited what the start of this validation means to GeneThera and to the future of BSE testing.”
SOURCE: GeneThera, Inc.
CONTACT: GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.net
Source:
GTHA – GeneThera, Inc.
Dr. Antonio Milici, CEO
GeneThera, Inc.
3930 Youngfield St.
Wheat Ridge, CO 80033
Fax: (303) 463 – 6377
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
